Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Research in Pelvic and Sacral Bone Sarcoma Diagnosis and Treatment
share announcement

Research in Pelvic and Sacral Bone Sarcoma Diagnosis and Treatment

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Pathophysiology".

Deadline for manuscript submissions: closed (31 March 2022)

Special Issue Editors

Dr. Matthew T. Houdek

E-Mail Website
Guest Editor
Department of Orthopedic Surgery, Mayo Clinic, Rochester, MN 55905, USA
Interests: soft tissue sarcoma; limb salvage; upper extremity; reconstruction
Special Issues, Collections and Topics in MDPI journals
Dr. Peter C. Ferguson

E-Mail Website
Guest Editor
Department of Surgery, University of Toronto, Toronto, ON M5G 1X5, Canada
Interests: bone sarcoma; soft tissue sarcoma; limb salvage; pelvic sarcoma

Special Issue Information

Dear Colleagues,

The pelvis is a common area for the development of bony sarcomas. Resection of pelvic bone sarcomas IS technically challenging due to the proximity of critical neurovascular structures, complex 3-dimensional anatomy, and adjacent organs. They are treated by a multidisciplinary team, and the decision to proceed with surgery, and the subsequent ultimate outcome of care, is based on tumor type, location, and operative plan. The incidence of these tumors has been increasing, with the most common histologies being chondrosarcoma, Ewing sarcoma, and osteosarcoma. When compared to the same tumor histology in the extremities, tumors located in the pelvis are known to have a poor prognosis, with a high rate of local recurrence and poor overall survival. Although prognosis is poor compared to the extremities, the only hope for cure in these patients requires a multidisciplinary approach.

Ongoing studies are needed to optimize patient care, with a focus on how the integration of different treatment modalities can improve patient outcome. Some of these areas include the use of proton and carbon-ion radiotherapy, investigating the appropriate dosing and schedule of chemotherapy, and how surgical advances such as navigated tumor resections can improve the outcome of patients with these tumors. This Special Issue will provide highlights on the role of these newer medical and surgical advances in the care of this complex patient population.

Dr. Matthew T. Houdek
Dr. Peter C. Ferguson
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Dr. Matthew T. Houdek
Dr. Peter C. Ferguson
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pelvic sarcoma
  • sacral sarcoma
  • proton radiotherapy pelvic sarcoma
  • chemotherapy for pelvic sarcoma
  • imaging pelvic tumors

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

14 pages, 1009 KiB  
Article
How Do the Outcomes of Radiation-Associated Pelvic and Sacral Bone Sarcomas Compare to Primary Osteosarcomas following Surgical Resection?
by Alexander L. Lazarides, Zachary D. C. Burke, Manit K. Gundavda, Rostislav Novak, Michelle Ghert, David A. Wilson, Peter S. Rose, Philip Wong, Anthony M. Griffin, Peter C. Ferguson, Jay S. Wunder, Matthew T. Houdek and Kim M. Tsoi
Cancers 2022, 14(9), 2179; https://doi.org/10.3390/cancers14092179 - 27 Apr 2022
Cited by 2 | Viewed by 1464
Abstract
Radiation-associated sarcoma of the pelvis and/or sacrum (RASB) is a rare but challenging disease process associated with a poor prognosis. We hypothesized that patients with RASB would have worse surgical and oncologic outcomes than patients diagnosed with primary pelvic or sacral bone sarcomas. [...] Read more.
Radiation-associated sarcoma of the pelvis and/or sacrum (RASB) is a rare but challenging disease process associated with a poor prognosis. We hypothesized that patients with RASB would have worse surgical and oncologic outcomes than patients diagnosed with primary pelvic or sacral bone sarcomas. This was a retrospective, multi-institution, comparative analysis. We reviewed surgically treated patients from multiple tertiary care centers who were diagnosed with a localized RASB. We also identified a comparison group including all patients diagnosed with a primary localized pelvic or sacral osteosarcoma/spindle cell sarcoma of bone (POPS). There were 35 patients with localized RASB and 73 patients with POPS treated with surgical resection. Patients with RASB were older than those with POPS (57 years vs. 38 years, p < 0.001). Patients with RASB were less likely to receive chemotherapy (71% for RASB vs. 90% for POPS, p = 0.01). Seventeen percent of patients with RASB died in the perioperative period (within 90 days of surgery) as compared to 4% with POPS (p = 0.03). Five-year disease-specific survival (DSS) (31% vs. 54% p = 0.02) was worse for patients with RASB vs. POPS. There was no difference in 5-year local recurrence free survival (LRFS) or metastasis free survival (MFS). RASB and POPS present challenging disease processes with poor oncologic outcomes. Rates of perioperative mortality and 5-year DSS are worse for RASB when compared to POPS. Full article
(This article belongs to the Special Issue Research in Pelvic and Sacral Bone Sarcoma Diagnosis and Treatment)
►▼ Show Figures

Figure 1

Review

Jump to: Research

24 pages, 1088 KiB  
Review
Management of Unresectable Localized Pelvic Bone Sarcomas: Current Practice and Future Perspectives
by Joaquim Soares do Brito, Miguel Esperança-Martins, André Abrunhosa-Branquinho, Cecilia Melo-Alvim, Raquel Lopes-Brás, João Janeiro, Dolores Lopez-Presa, Isabel Fernandes, José Portela and Luis Costa
Cancers 2022, 14(10), 2546; https://doi.org/10.3390/cancers14102546 - 22 May 2022
Cited by 1 | Viewed by 2584
Abstract
Bone sarcomas (BS) are rare mesenchymal tumors usually located in the extremities and pelvis. While surgical resection is the cornerstone of curative treatment, some locally advanced tumors are deemed unresectable and hence not suitable for curative intent. This is often true for pelvic [...] Read more.
Bone sarcomas (BS) are rare mesenchymal tumors usually located in the extremities and pelvis. While surgical resection is the cornerstone of curative treatment, some locally advanced tumors are deemed unresectable and hence not suitable for curative intent. This is often true for pelvic sarcoma due to anatomic complexity and proximity to vital structures, making treatment options for these tumors generally limited and not unanimous, with decisions being made on an individual basis after multidisciplinary discussion. Several studies have been published in recent years focusing on innovative treatment options for patients with locally advanced sarcoma not amenable to local surgery. The present article reviews the evidence regarding the treatment of patients with locally advanced and unresectable pelvic BS, with the goal of providing an overview of treatment options for the main BS histologic subtypes involving this anatomic area and exploring future therapeutic perspectives. The management of unresectable localized pelvic BS represents a major challenge and is hampered by the lack of comprehensive and standardized guidelines. As such, the optimal treatment needs to be individually tailored, weighing a panoply of patient- and tumor-related factors. Despite the bright prospects raised by novel therapeutic approaches, the role of each treatment option in the therapeutic armamentarium of these patients requires solid clinical evidence before becoming fully established. Full article
(This article belongs to the Special Issue Research in Pelvic and Sacral Bone Sarcoma Diagnosis and Treatment)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop